These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 24366912)

  • 1. Lactate dehydrogenase A silencing in IDH mutant gliomas.
    Chesnelong C; Chaumeil MM; Blough MD; Al-Najjar M; Stechishin OD; Chan JA; Pieper RO; Ronen SM; Weiss S; Luchman HA; Cairncross JG
    Neuro Oncol; 2014 May; 16(5):686-95. PubMed ID: 24366912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.
    Huang GH; Du L; Li N; Zhang Y; Xiang Y; Tang JH; Xia S; Zhang EE; Lv SQ
    Cancer Lett; 2018 Sep; 432():93-102. PubMed ID: 29885519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
    Yao J; Chakhoyan A; Nathanson DA; Yong WH; Salamon N; Raymond C; Mareninov S; Lai A; Nghiemphu PL; Prins RM; Pope WB; Everson RG; Liau LM; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2019 Sep; 21(9):1184-1196. PubMed ID: 31066901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.
    Perycz M; Dabrowski MJ; Jardanowska-Kotuniak M; Roura AJ; Gielniewski B; Stepniak K; Dramiński M; Ciechomska IA; Kaminska B; Wojtas B
    Acta Neuropathol Commun; 2024 May; 12(1):72. PubMed ID: 38711090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
    Mo H; Magaki S; Deisch JK; Raghavan R
    J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
    Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
    J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
    Gerardo Valadez J; Grover VK; Carter MD; Calcutt MW; Abiria SA; Lundberg CJ; Williams TV; Cooper MK
    Cancer Lett; 2013 Jan; 328(2):297-306. PubMed ID: 23063752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
    Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
    Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
    Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
    Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.